RecruitingPhase 4NCT07271771
The Effect of Denosumab on Muscle and Strength and Insulin Sensitivity
Sponsor
Aarhus University Hospital
Enrollment
40 participants
Start Date
May 21, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
Randomized, placebo controlled prospective trial evaluating the effect of denosumab on insulin sensitivity and muscle strength.
Eligibility
Sex: FEMALEMin Age: 40 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Denosumab and a drug called Saline (0.9% NaCl) for people with osteoporosis. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 40 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGDenosumab
Denosumab 60 mg
DRUGSaline (0.9% NaCl)
Placebo
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07271771
Related Trials
U.S. Prospective Evaluation of EPIONE Device for Percutaneous MSK Procedures
NCT073255783 locations
The Optimised Use of Romozosumab Study
NCT060592221 location
Can Serum Lumican Level Identify a Hidden Fragility Phenotype Beyond Bone Mineral Density in Postmenopausal Women?
NCT076770721 location
Functional Muscle-Bone Incongruity Index (FKUI): A Prospective Observational Study
NCT076770331 location
Safety and Efficacy Clinical Trial of the Vessel-X® Bone Filling Container System
NCT076654242 locations